The efficacy and safety of monopolar radiofrequency for treatment of moderate-to-severe recalcitrant acne

Phase 4

• Conditions: Patient with moderate to severe recalcitrant acne; monopolar radiofrequency, moderate to severe recalcitrant acne

• Registration Number: TCTR20220627002
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-27
• Study Completion: 2023-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Aged from 18 years or older
2. Were diagnosed with moderate to severe recalcitrant acne by dermatologist
3. The patient who were not responded by standard treatment, for example, topical treatments and oral antibiotics at least 3 month and have to hold any treatment for 1 month

Exclusion Criteria

1. Patients who are pregnant, lactating, and postpartum within 1 year
2. Patients who taking oral isotretinoin within 1 year
3. Patients with other skin disease, or having infection at the area of face
4. Immunocompromised patients
5. Patients with hypertrophic scar or keloid
6. Patients with history of Cushing syndrome or Ehlers-Danlos syndromd
7.Patients with cancers or skin cancers
8.Patients with mental disorders
9.Patiens with chemical peels within 1 month
10. patient with herpes simplex infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Investigator Global Assessment (IGA) Baseline, 1, 2, 4, 7 months Antera,Acne count Baseline, 1, 2, 4, 7 months Counting

Secondary Outcome Measures

Name	Time	Method
Sebum level Baseline, 1, 2, 4, 7 months Sebumeter,Pain score Baseline, 1, 2, 4, 7 months Visual Analog Scale,Safety Baseline, 1, 2, 4, 7 months Adverse events,Dermatology Life Quality Baseline and 7 month DLQI